NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NAMS
NewAmsterdam Pharma Company N.V. (NAMS) P/E ratio
NewAmsterdam Pharma Company N.V. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 22.7× (September 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 8.1× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 10 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| MBX MBX Biosciences, Inc. compare | n/m |
| BEAM Beam Therapeutics Inc. compare | n/m |
| ZLAB Zai Lab Limited Unsponsored ADR compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| PGEN Precigen, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.9× |
| ADMA ADMA Biologics Inc compare | 14.8× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)